GlassScriptPhysician profile
Gregory O Spellman
NPI 1407083207
$8,469.54
in general payments reported to CMS, 2019-2025
18 companies · $1,230 in 2025
The $1,230 reported for 2025 was more than what 77% of Pain Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,328 · 2020: $1,162 · 2021: $948 · 2022: $941 · 2023: $873 · 2024: $1,987 · 2025: $1,230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,258 · Consulting Fee: $833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,257.61 |
| Consulting Fee | $832.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $7,554.32 | 2019-2025 | Wavewriter Alpha Prime 16, Na, General - Therapies |
| Scilex Pharmaceuticals INC. | $142.57 | 2021-2024 | Ztlido |
| Fidia Pharma USA INC. | $130.72 | 2021-2023 | Hym/Hyn |
| Nevro Corp. | $118.18 | 2019-2024 | Senza |
| Globus Medical, INC. | $90.75 | 2025 | Senza |
| Biodelivery Sciences International, INC. | $85.38 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $66.44 | 2020-2024 | Nucynta, Belbuca |
| Vertex Pharmaceuticals Incorporated | $54.37 | 2024-2025 | |
| Abbott Laboratories | $49.70 | 2020 | |
| Ermi LLC | $30.00 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.15 | 2020-2021 | |
| Horizon Therapeutics Plc | $28.18 | 2020 | |
| Avanos Medical | $18.94 | 2019 | |
| Arbor Pharmaceuticals, INC. | $16.37 | 2019 | |
| Vericel Corporation | $15.95 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $13.73 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $12.92 | 2023 | |
| Sentynl Therapeutics, INC. | $11.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Spellman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.